Dernières nouvelles
Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA) LEXINGTON, Mass., September 21, 2023, –Hemanext Inc., a leading innovator in blood processing, storage, and...
Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously,...
Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
LEXINGTON, Mass., July 5, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region's premier trade association...
Hemanext annonce un partenariat avec The Aplastic Anemia & MDS International Foundation (AAMDSIF)
LEXINGTON, Mass., 02 février 2022, PR NEWSWIRE – Hemanext Inc. (Hemanext ou la Société), un innovateur de premier plan dans le traitement, le stockage et la technologie transfusionnelle du sang, est fier d’annoncer un nouveau partenariat avec The Aplastic Anemia &...
Hemanext ONE devient le premier système de traitement et de stockage du sang à recevoir un sceau de conformité aux normes de l’AABB
LEXINGTON, Mass., 24 Janvier 2022, PR NEWSWIRE – Hemanext Inc. a annoncé aujourd’hui que Hemanext ONE®, son système novateur de traitement et de stockage de globules ruges, a été reconnu par the Association for the Advancement of Blood & Biotherapies (AABB), une...